TORIXAVA 120 MG (ETORICOXIB) — FILM-COATED TABLETS

Medical Product Description | Selective COX-2 Inhibitor | Prescription Medicine

Product Overview

Torixava 120 mg contains etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the non-steroidal anti-inflammatory drug (NSAID) class. It helps relieve pain and inflammation by reducing the production of prostaglandins, substances involved in the body's inflammatory and pain responses.

Etoricoxib is used for specific inflammatory joint conditions and certain acute pain conditions. The 120 mg strength is a high-dose formulation intended for selected indications and short-term use under medical supervision.

Active ingredient: Etoricoxib 120 mg per film-coated tablet.
Dosage form: Oral film-coated tablets.
Pack size: 10 tablets.
Therapeutic class: Selective COX-2 inhibitor; non-steroidal anti-inflammatory drug (NSAID).

Indications and Potential Benefits

When prescribed for an appropriate indication, etoricoxib may help:

Acute gouty arthritis: Relieve acute gout-related joint pain, swelling, and inflammation.
Acute pain: Provide short-term relief in selected acute pain conditions where etoricoxib is indicated.
Inflammatory symptoms: Reduce pain and inflammation associated with certain musculoskeletal conditions, although lower strengths are generally used for chronic arthritis management.

Important: The 120 mg strength is specifically used for certain indications, including acute gouty arthritis. It is not the usual recommended strength for routine osteoarthritis or rheumatoid arthritis treatment.

Mechanism of Action

Etoricoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which contributes to prostaglandin production during inflammation. By reducing prostaglandin synthesis, it helps decrease pain and inflammation. Its relative selectivity for COX-2 means it generally has less effect on COX-1-mediated gastric protection than traditional non-selective NSAIDs; however, it can still cause gastrointestinal complications.

Dosage and Directions for Use

For acute gouty arthritis: The recommended adult dose is 120 mg once daily, for a maximum of 8 days.
For other acute pain conditions: The appropriate dose and duration depend on the specific indication and the applicable product information.
Swallow the tablet with water. It may be taken with or without food.
Use the lowest effective dose for the shortest possible duration, as directed by the prescribing physician.

Do not exceed the prescribed dose or use Torixava 120 mg for longer than recommended. The appropriate dose varies by condition, and the 120 mg strength should not be used routinely for chronic arthritis.

Possible Side Effects

Potential adverse effects of etoricoxib include:

Common or reported effects: Abdominal pain, indigestion, nausea, headache, dizziness, swelling of the legs or feet, and increased blood pressure.
Cardiovascular risks: Increased risk of heart attack or stroke, particularly in susceptible patients and with higher doses or prolonged use.
Gastrointestinal risks: Stomach or intestinal ulcers, bleeding, and, rarely, perforation.
Renal effects: Worsening kidney function and fluid retention.
Other serious reactions: Liver problems, severe allergic reactions, and serious skin reactions.

Seek urgent medical attention for chest pain, sudden weakness or difficulty speaking, breathing difficulties, facial or throat swelling, black stools, vomiting blood, or severe skin reactions.

Warnings and Precautions

Consult a physician before use, particularly if the patient has:

High blood pressure, heart failure, established cardiovascular disease, or a history of stroke.
Kidney or liver impairment.
A history of stomach ulcers or gastrointestinal bleeding.
Asthma or allergic reactions associated with aspirin or other NSAIDs.
Fluid retention or conditions that may be worsened by increased blood pressure.

Contraindications and important restrictions:

Do not use in patients with active peptic ulcers or gastrointestinal bleeding.
Contraindicated in patients with certain established cardiovascular or cerebrovascular diseases, uncontrolled hypertension, or severe kidney or liver impairment, according to applicable product information.
Avoid during pregnancy; etoricoxib is contraindicated during the third trimester. Consult a physician regarding pregnancy or breastfeeding.
Not intended for children or adolescents under 16 years of age under the referenced product information.

Etoricoxib should not be combined with other NSAIDs, such as ibuprofen, diclofenac, or naproxen, unless specifically directed by a physician. It may interact with anticoagulants, diuretics, ACE inhibitors, ARBs, lithium, methotrexate, and other medicines.

Storage

Store according to the instructions on the original package.
Keep out of the reach and sight of children.
Do not use after the expiry date.
Do not use tablets if the packaging is damaged or the tablets show signs of deterioration.

References

The following sources provide authoritative prescribing and patient-safety information:

Electronic Medicines Compendium (eMC) — Etoricoxib 120 mg: Summary of Product Characteristics. (.org.uk)
Singapore National Drug Formulary — Etoricoxib 120 mg Product Information. (.gov.sg)
Electronic Medicines Compendium (eMC) — Etoricoxib Patient Information Leaflet. (.org.uk)

Patient Disclaimer

This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Torixava 120 mg (etoricoxib) should be used only as prescribed by a qualified healthcare professional. Do not start, stop, or change the dose without consulting your physician or pharmacist. Always read the approved patient leaflet before use. This product is not intended to diagnose, treat, cure, or prevent any disease without appropriate medical assessment.